Current status of the biology and treatment of acute non-lymphocytic leukemia in children (report from the ANLL strategy group of the Children's Cancer Study Group.
Major advances have been made in the past 10 yr in both the understanding of the biologic characteristics of acute nonlymphocytic leukemia and in the treatment of patients with this disease. Advances in the biologic characteristics include: a better understanding of the nature of leukemic cell proliferation and differentiation; a clearer description of the morphological, histochemical, and ultrastructural characteristics of leukemic cells; a recognition that a high percentage of patients may have specific cytogenetic abnormalities; and a recognition that biochemical differences exist between acute nonlymphocytic leukemia (ANLL) and acute lymphoblastic leukemia (ALL). Today, over 70% of children with ANLL can be induced into a complete remission and over 25% are remaining in a continuous remission for over 2 yr. In spite of these improved results, the best method of extending remissions is unknown. It is unlikely that better results of therapy will be achieved in the future by tailoring the treatment according to the biologic characteristics of the patient, since it appears that ANLL is a heterogeneous group of diseases.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation; D001927:Brain Diseases / Q000517:prevention & control; D002449:Cell Aggregation; D002454:Cell Differentiation; D003582:Cytogenetics; D004314:Down Syndrome / Q000097:blood; D004317:Doxorubicin / Q000627:therapeutic use; D006098:Granulocytes / Q000502:physiology; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007278:Injections, Spinal; D007700:Kinetics; D007938:Leukemia / Q000503:physiopathology* / Q000628:therapy; D007958:Leukocyte Count; D008264:Macrophages / Q000502:physiology; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008938:Mitosis; D010587:Phagocytosis; D011379:Prognosis; D011955:Receptors, Drug; D014212:Tretinoin / Q000627:therapeutic use
D011955:Receptors, Drug; D014212:Tretinoin; D004317:Doxorubicin; D008727:Methotrexate